West Pharmaceutical Services, Inc. Aktie News

West Pharmaceutical Services, Inc. (WST) Discusses Integrated Prefillable Syringe Systems to Streamline Drug Development and Reduce Complexity Transcript

EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, and will follow with a conference call to discuss the results and business expectation...

West Pharmaceutical Services (WST) stock should be included in your watchlist. Here's why – it is currently operating within the support zone ($224.83 – $248.49), prices from which it has previously bounced significantly.

The coming week will put Big Tech earnings and the Federal Reserve firmly in focus, with markets bracing for key signals on growth, inflation, and policy direction.

Showcasing Leadership in Drug Delivery Solutions and Approaches to Combination Products EXTON, Pa., Jan. 20, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced participation at Pharmapack 2026 in Paris, France to showcase its leadership and expertise on industry challenges and trends in packa...

West Pharmaceutical Services, Inc. (WST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Milestone marks progress against AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decade to broadly support innovation and expand critical manufacturing capabilities and capacity Supports production of AbbVie's current and next-generation immunology and neuroscience medicines Transaction anticipated to close in mid-2026 NORTH CHICAGO,...

EXTON, Pa., Jan. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the company has reached a definitive agreement to sell all manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for total consideration o...